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Purpose: This dose-response study was designed to determine
the most appropriate dose of ropivacaine 0.5% injected via an
indwelling femoral catheter for perioperative peripheral analgesia
for total knee replacement (TKR).
Methods: 84 patients were allocated randomly to four groups and
received, via a femoral catheter,  either 15, 20, 25 or 30 mL of
ropivacaine 0.5% in a double-blind fashion. An anterior sciatic block
with 20 mL bupivacaine 0.5% was also performed. The evolution
of sensory block of femoral, obturator and lateral femoral cuta-
neous nerves and motor block of femoral nerve were tested every
five minutes during the first 30 min. The percentage of patients with
complete sensory block of both femoral and obturator nerves
determined success rate. General anesthesia was then induced.
After surgery, patient-controlled analgesia (PCA) with ropivacaine
0.2% was available via the femoral catheter. The interval between
the initial injection and the first PCA administration determined
duration of action. 
Results: The duration of action was not different between the four
solutions tested i.e., 534 ± 379 min for 15 mL, 799 ± 364 min for
20 mL, 624 ± 342 min for 25 mL and 644 ± 266 min for 30 mL.
The percentage of patients with complete sensory femoral and
obturator blocks was, respectively, 60%, 95%, 85% and 70% for
15, 20, 25 and 30 mL (P = 0.008/15 mL vs 20 mL). 
Conclusion: Although there is no difference in duration of analge-
sia, because of better sensory spread, 20 mL of ropivacaine 0.5%
appears to be the most appropriate dose for peripheral analgesia
after TKR.
Objectif : L’étude dose-réponse visait à déterminer la meilleure dose
de ropivacaïne à 0,5 % injectée par cathéter fémoral à demeure pour
l’analgésie périopératoire périphérique lors d’une arthroplastie totale
du genou (ATG).
Méthode : Nous avons réparti au hasard, en quatre groupes, 84
patients qui ont reçu par cathéter fémoral 15, 20, 25 ou 30 mL de
ropivacaïne à 0,5 % en double insu. Un bloc sciatique antérieur a
aussi été réalisé avec 20 mL de bupivacaïne à 0,5 %. L’évolution du
bloc sensitif des nerfs fémoral, obturateur et cutané latéral de la cuisse
et du bloc moteur du nerf fémoral a été vérifiée toutes les cinq mi-
nutes pendant les 30 premières minutes. Le pourcentage de patients
qui présentait un bloc sensitif complet des nerfs fémoral et obturateur
a déterminé le taux de succès. L’anesthésie générale a ensuite été
induite. Après l’opération, l’analgésie auto-contrôlée (AAC) avec de la
ropivacaïne à 0,2 % était disponible par cathéter fémoral. L’intervalle
entre l’injection initiale et la première administration d’AAC a donné la
durée d’action.
Résultats : La durée d’action a été comparable dans tous les groupes :
534 ± 379 min avec 15 mL, 799 ± 364 min avec 20 mL, 624 ± 342
min avec 25 mL et  644 ± 266 min avec 30 mL. Le pourcentage de
patients présentant un bloc sensitif complet des nerfs fémoral et obtu-
rateur a été respectivement de 60 %, 95 %, 85 % et 70 % pour les
doses de 15, 20, 25 et 30 mL (P = 0,008/15 mL vs20 mL).
Conclusion : Même si la durée de l’analgésie est équivalente, grâce
à une meilleure diffusion sensitive, 20 mL de ropivacaïne à 0,5 %
semble être la dose la plus appropriée pour l’analgésie périphérique
après une ATG.
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Duration of analgesia is similar when 15, 20, 25
and 30 mL of ropivacaine 0.5% are administered
via a femoral catheter
[La durée de l’analgésie est similaire quand 15, 20, 25 et 30 mL de ropivacaïne à
0,5 % sont administrés par un cathéter fémoral]
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N the last decade, analgesia through neuraxial
and peripheral nerve blocks has been shown to
be superior to iv opioids and has gained
increased acceptance for pain relief during
total knee replacement (TKR).1,2 Although continu-
ous epidural and continuous femoral nerve blocks
provide excellent analgesia of comparable quality,
because of fewer side effects, continuous femoral
nerve blocks appear to be the most appropriate anal-
gesic technique for this surgical procedure.1,2
Sensory innervation of the knee is provided by the
lumbar plexus and sciatic nerve.3 The lumbar plexus
supply is predominant and includes the femoral nerve
(anterior aspect of the knee) and the obturator nerve
(medial aspect of the knee). Blockade of these two
nerves is mandatory to obtain satisfactory analgesia
during TKR surgery. The third main branch of the
lumbar plexus, the lateral femoral cutaneous nerve,
provides sensory supply to the lateral side of the thigh,
and its blockade allows better tolerance to thigh
tourniquet during TKR. A local anesthetic can be
administered in the lumbar plexus using the anterior
3-in-1 block4 or a posterior approach.5 The anterior
approach does not consistently produce anesthesia of
the obturator and lateral femoral cutaneous nerves,6,7
whereas the posterior approach appears to be more
reliable in blocking the three major branches.6,8
By introducing an indwelling femoral catheter in a
cephalad direction, one can expect that the tip of the
catheter will be located much closer to the site of
injection achieved by a posterior approach to the lum-
bar plexus. Thus a more reliable blockade of the three
main branches can be expected. In addition, the high-
er cephalad administration of a local anesthetic could,
in theory, allow a decrease in the volume and dose of
a local anesthetic usually given for a 3-in-1 block,
which varies between 30 and 40 mL.6,7,9–11 A reduc-
tion in dose and volume could decrease the risk of sys-
temic toxicity in the context of peripheral block for
TKR when the combination of both femoral and sci-
atic blocks is followed by the administration of local
anesthetics over several days via a femoral catheter. 
This study was designed to evaluate, in patients
undergoing TKR, the analgesic effects of various doses
of ropivacaine 0.5% injected via a femoral catheter
threaded 12 cm in a cephalad direction. The main
endpoint was duration of analgesia and the ancillary
endpoints were success rate of blockade and quality of
postoperative analgesia.
Methods
After approval from the Ethics Committee of our
institution, 84 orthopedic patients, ASA physical sta-
tus class I–III, scheduled to undergo a TKR under
combined peripheral block/general anesthesia, gave
informed consent to participate in this study.
Hemorrhagic diathesis, peripheral neuropathy, local
infection, allergy to amide local anesthetics, preopera-
tive use of opioids and psychiatric disease or dementia
were exclusion criteria.
Patients received midazolam 7.5 mg orally 30 to 45
min before their scheduled arrival in the operating
room and were monitored with continuous electro-
cardiogram, peripheral oxygen saturation, and non-
invasive blood pressure measurement. A peripheral
venous catheter was inserted in all patients, whereas
more invasive monitoring such as urinary, central
venous and arterial catheters were placed only when
required by the patient’s clinical condition. 
Prior to insertion of a femoral catheter (Contiplex®
D Set, Braun, Melsungen, Germany), all patients
received fentanyl 1.5 µg·kg–1 iv. Using Winnie’s land-
marks,4 the femoral nerve was located using a nerve
stimulator (Stimuplex® HNS 11, Braun, Melsungen,
Germany). After observing contraction of the quadri-
ceps femoris (patella ascension) at a stimulus rate of 2
Hz, a stimulus duration of 0.1 msec and an amplitude
lower than 0.4 mA, 2 mL of normal saline were inject-
ed in the sheath before the catheter was introduced to
a depth of 12 cm from the needle tip. 
Using sealed envelopes, patients were randomly
assigned to one of four study groups and received, in
a double-blind fashion, one of the following solutions
via the femoral catheter:
- Group Ropivacaine-15 mL (R15): 15 mL of 
ropivacaine 0.5% = 75 mg
(Naropin®, Astra, Dietikon, Switzerland)
- Group Ropivacaine 20 mL (R20): 20 mL of 
ropivacaine 0.5% = 100 mg
- Group Ropivacaine 25 mL (R25): 25 mL of 
ropivacaine 0.5% = 125 mg
- Group Ropivacaine 30 mL (R30): 30 mL of 
ropivacaine 0.5% = 150 mg
The study solutions were prepared and injected by
the attending anesthesiologist who was not involved
in patient care or data collection. Sensory block of the
three main branches was assessed by the anesthesiolo-
gist in charge, every five minutes during the first 30
min after injection, by loss of temperature discrimina-
tion with ether drops. Testing was performed on the
anterior aspect of the knee (femoral nerve), medial
aspect of the knee (obturator nerve) and the lateral
aspect of the thigh (lateral femoral cutaneous nerve).
The block was considered complete when no cold dis-
crimination was observed, partial when cold discrimi-
I
nation was decreased, and absent when normal cold
discrimination was observed. Femoral motor block
was also assessed during the same period by testing
knee extension, and was considered complete when no
extension was observed, partial when quadriceps
motor force was decreased and absent when normal
quadriceps function was observed. The percentage of
patients with complete sensory block of the femoral
and obturator nerves after 30 min determined the
success rate of the tested dose of ropivacaine 0.5%.
Thereafter a sciatic nerve block with 20 mL bupi-
vacaine 0.5% (Carbostesin®, Astra, Dietikon,
Switzerland) with epinephrine 1:200,000 was per-
formed in all patients using an anterior approach.12 A
100-mm long needle was attached to a nerve stimula-
tor and the anesthetic solution was injected after
obtaining dorsal or plantar flexion of the foot with
similar stimulation variables as those described above.
The block was assessed by the same investigator, after
surgery, in the recovery room by loss of temperature
discrimination with ether drops on the dorsal side of
the foot.
General anesthesia was induced with sodium
thiopental 4 to 6 mg·kg–1 and rocuronium 0.6
mg·kg–1 and maintained with isoflurane (end-tidal
0.3–1%) and nitrous oxide 60 to 70% in oxygen.
Intraoperatively, fentanyl 1 µg·kg–1 was given when
heart rate and/or mean arterial blood pressure
increased more than 30% above pre-induction levels
with 1% end-tidal isoflurane concentrations. 
After surgery, a patient-controlled analgesia (PCA)
device was set to deliver 20 mL boluses of ropivacaine
0.2% with a lockout of 120 min via the femoral
catheter. All patients were instructed to quantify post-
operative pain intensity on a visual analogue scale
(VAS) ranging from 0 to 10 cm and to locate pain,
when possible, in either the anterior or posterior knee
area. They were further instructed to use the PCA
device when the pain score in the anterior knee area
was above 3 cm, or to ask for rescue morphine in the
event of persistent pain in the posterior knee area. The
interval between the initial ropivacaine injection and
the first PCA injection determined the duration of
analgesic action of the tested dose of ropivacaine 0.5%.
Pain scores at rest every four hours after the initial
ropivacaine injection and over 24 hr were recorded by
nurses in charge. Intervals between the initial ropiva-
caine injection (time zero) and first PCA injection, as
well as consumption of ropivacaine 0.2% over 24 hr
were recorded by a single investigator blinded to
group assignment. 
Rescue morphine (0.1 mg·kg–1 sc, maximum six
doses/24 hr) was prescribed for a residual pain score in
the anterior knee area higher than 3 cm during the lock-
out interval or for pain in the posterior knee area.
Paracetamol 1 g (Dafalgan®, UPSA, Baar, Switzerland)
and/or ibuprofen 400 mg (Brufen®, Knoll, Liestal,
Switzerland) were given orally for other pains
(headache, back pain, arthritic pain) as required.
Analgesic requirements over 24 hr were obtained from
the nurses’ records.
According to our previous report where duration of
analgesia with 20 mL ropivacaine 0.5% was 657 ± 345
min,13 the sample size was computed to detect an
increase of duration of 50%, i.e., 5 ½ hr with a power
of 80% or greater and a 5% or less chance of a type 1
error (ß = 0.2; two-tailed α = 0.05). For four study
groups a minimal sample of 18 patients per group met
these criteria. Taking into account possible catheter
failure or inappropriate use of the PCA pump, we
decided to test 21 patients per group.
Data are expressed as mean ± SD or number (n)
and percentage (%). The statistical analyses were per-
formed using analysis of variance (ANOVA) with
Bonferroni post-hoc or Chi-square as required, using
the Statistical Package for the Social Sciences (SPSS
for Windows, version 9.0, Chicago, IL, USA). A P
value < 0.05 was considered statistically significant.
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TABLE I Patient characteristics (mean ± SD)
Group Ropivacaine 0.5% Ropivacaine 0.5% Ropivacaine 0.5% Ropivacaine 0.5% P value
15 mL 20 mL 25 mL 30 mL
(n = 20) (n = 20) (n = 20) (n = 20)
Age (yr) 72 ± 8 72 ± 9 68 ± 9 69 ± 7 NS
Height (cm) 166 ± 9 158 ± 25 161 ± 27 163 ± 8 NS
Weight (kg) 81 ± 12 74 ± 12 82 ± 17 76 ± 13 NS
Female/male 12/8 14/6 10/10 15/5 NS
ASA I-II/III 13/7 17/3 14/6 16/4 NS
ASA = American Society of Anesthesiologists physical status.
Results
Four of the 84 patients enrolled (one in each group)
were withdrawn from the study for the following rea-
sons: obvious failure of femoral catheter in three
patients and impossibility to reliably test the block in
one patient. Among the remaining 80 patients, 20
were allocated to each group. No differences between
the four groups were noted with respect to patient
characteristics (Table I).
The success rate of blockade of each nerve 30 min
after the injection of the local anesthetic is presented
in Table II. The differences between the groups are
not significant. Complete block of both the femoral
and obturator sensory nerves was observed in 12
patients in R15, 19 in R20, 17 in R25 and 14 in R30
group. The difference between R15 and R20 group is
significant (P = 0.008). 
The duration of anesthesia, defined as time
between ropivacaine 0.5% injection and extubation
(about three hours), and tourniquet time (about 30
min) were comparable between the four groups.
During surgery, no patient in groups R20 and R30,
one patient in the R15 group and two in the R25
group received 75 µg of fentanyl for hypertension
during tourniquet inflation. 
In the recovery room, complete sensory sciatic
block was present in 19 out of 20 patients in groups
R15, R20 and R30 and in 18 out of 20 patients in
group R25. The block was partial in one patient of
each group and absent in one patient of the R25
group.
Five patients (one in groups R15, R25 and R30
and two in group R20) were not considered for analy-
sis of duration of analgesia because the first ropiva-
caine 0.2% administration was incompatible with the
study design (the PCA pump was activated by the
patient or patient’s family to test the device and not
for pain treatment).
The duration of analgesia was not statistically dif-
ferent between the four study groups i.e., 534 ± 379
min in R15, 799 ± 364 min in R20, 624 ± 342 min in
R25 and 644 ± 266 min in the R30 group. 
The 24 hr consumption of ropivacaine 0.2% was
significantly lower in group R20 (44 ± 29 mL) when
compared to group R15 (83 ± 46 mL), (P = 0.009)
and group R25 (79 ± 37 mL), (P = 0.027), but not
different from group R30 (67 ± 28 mL). During this
period six patients in R15, three in R20, four in R25
and three in R30 received one dose of rescue mor-
phine (always for posterior knee pain and always after
the first PCA injection of ropivacaine 0.2%).
The evolution of pain scores of both anterior and
posterior aspects of the knee, over 24 hr after block-
ade, is illustrated in the Figure. The mean values
remained under 3 cm in the four groups. Four hours
after the initial injection, pain scores in group R15
were higher when compared to R20 (P = 0.02), R25
(P = 0.031) and R30 (P = 0.013).
A comparable number of patients in each group
received paracetamol and/or ibuprofen during the
first 24 hr, 42% in R15, 44% in R20, 32% in R25 and
37% in R30 group.
Discussion 
Our results show that the duration of analgesia was
similar in all groups. However, considering the initial
sensory spread, postoperative ropivacaine 0.2%
requirements and VAS values (Figure), 20 mL of ropi-
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TABLE II Success rate of blocks after 30 min
Group Ropivacaine 0.5% Ropivacaine 0.5% Ropivacaine 0.5% Ropivacaine 0.5% P value
15 mL 20 mL 25 mL 30 mL
(n = 20) (n = 20) (n = 20) (n = 20)
Sensory femoral complete 13 (65%) 19 (95%) 17 (85%) 15 (75%) NS
partial 6 (30%) 1 (5%) 3 (15%) 4 (20%) NS
absent 1 (5%) 0 0 1 (5%) NS
Sensory obturator complete 14 (70%) 19 (95%) 17 (85%) 16 (80%) NS
partial 3 (15%) 1 (5%) 2 (10%) 4 (20%) NS
absent 3 (15%) 0 1 (5%) 0 NS
Sensory lateral complete 6 (30%) 12 (60%) 8 (40%) 10 (50%) NS
femoral cutaneous partial 8 (40%) 6 (30%) 7 (35%) 7 (35%) NS
absent 6 (30%) 2 (10%) 5 (25%) 3 (15%) NS
Motor femoral present 14 (70%) 19 (95%) 14 (70%) 16 (80%) NS
partial 6 (30%) 1 (5%) 6 (30%) 4 (20%) NS
absent 0 0 0 0 NS
Number of patients with blocked nerves with % in parentheses.
vacaine 0.5% appear to be superior to 15 mL of ropi-
vacaine 0.5%, whereas 25 and 30 mL of the same ropi-
vacaine solution do not provide any further advantage.
Dose response studies using femoral plexus blocks
are incomplete and inconclusive. With a single injec-
tion of local anesthetic at the femoral crease,
Seeberger7 found no difference in the extension of a
3-in-1 block between 20 mL and 40 mL of mepiva-
caine 1%. By using an up-and-down method, Casati
reported that the minimum local anesthetic volume
required to provide a successful femoral nerve block in
50% of subjects was 14 mL of ropivacaine 0.5% and 15
mL of bupivacaine 0.5%14 and that the average dose
was 23 mL of ropivacaine 0.5%.15 Using indwelling
femoral catheters, different authors injected between
20 and 40 mL of different anesthetic solutions with or
without epinephrine and/or opiates.1,2,13,16–19 Among
these, only one reported the duration of analgesia of
the initial dose of local anesthetic,13 only one report-
ed extent of the block,16 and a dose response study has
never been described previously. Our study in patients
undergoing TKR demonstrates that there was no sig-
nificant difference in duration of analgesia between
the four anesthetic solutions studied. In our opinion,
performing a sciatic nerve block improved our ability
to measure this variable.
Although a sciatic block is mandatory to perform
TKR surgery when using a peripheral block, there is
controversy regarding it’s usefulness for postoperative
pain relief after surgery. Allen observed no advantage
on postoperative analgesia when a sciatic block is com-
bined with a femoral block.20 Capdevila using a con-
tinuous femoral block with a mixture of local anes-
thetic, clonidine and morphine reported that the pain
located in the posterior knee area was disturbing in
patients undergoing TKR.2 Recently we have shown
that a sciatic block was required in two thirds of
patients to improve postoperative pain relief after
TKR.21 We feel that, in the present study, a long last-
ing sciatic nerve block contributed to the excellent
analgesia observed during the first 24 postoperative
hours (Figure), and that the small doses of fentanyl
given in all patients before the catheter insertion and
in only three during surgery did not affect the time of
first ropivacaine 0.2% request. Since rescue morphine
was always given after the first PCA administration of
ropivacaine 0.2%, there is a high probability that these
morphine injections were required for pain originating
from the anterior or medial knee areas innervated by
branches of the femoral plexus, thus allowing a very
precise determination of duration of analgesia with
different doses of ropivacaine 0.5%. However, we have
no valid explanation as to why there is no difference in
duration of analgesia with different volumes of local
anesthetic. Variability of the catheter tip location may
be involved.
In our study, the position of catheters was not ver-
ified by x-ray. Thus, catheter coiling or migration
must be taken into account. Ganapathy22 evaluated,
by computed tomography, the position of 20 femoral
catheters advanced 20 cm cranially. Only eight (40%)
were placed in an “ideal” position, defined as location
of the catheter tip within 2 cm of the cephalad portion
of the sacroiliac joint and the lateral borders of L4 to
L5 vertebrae. The position of the remaining catheters
was not reported. Capdevila16 verified radiologically
the position of 100 femoral catheters inserted 16 to
20 cm in the fascia sheath and reported that, in 23%
of the patients, the tip of the catheter reached the
lumbar plexus, in 33% lay deep in the medial part of
the fascia iliaca and in 37% was placed in the lateral
part of the fascia iliaca. After injection of 30 mL of a
mixture of lidocaine 2% and bupivacaine 0.5%, a 3-in-
1 block was obtained in 91% of patients when the
catheter was placed in the lumbar plexus. With the
catheter positioned more medially, femoral and obtu-
rator nerves were blocked in 84% and the lateral
femoral cutaneous nerve in 52% of patients. However,
when the catheters were placed more laterally, femoral
and lateral femoral cutaneous nerves were blocked in
91% and the obturator nerve in only 27% of patients.
We inserted the catheter 12 cm i.e., 4 to 8 cm less than
Ganapathy or Capdevila, respectively, and obtained,
with 20 mL ropivacaine 0.5%, femoral and obturator
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FIGURE Evolution of pains scores of both anterior and posteri-
or aspects of the knee over 24 hr after nerve blockade in the four
groups (mean ± SD). R15 = 15 mL of ropivacaine 0.5%, R20 = 20
mL of ropivacaine 0.5%, R25 = 25 mL of ropivacaine 0.5% and
R30 = 30 mL of ropivacaine 0.5%. *p < 0.05 between R15 and
the other groups four hours after the initial injection.
sensory blocks in 95% of patients, whereas the lateral
femoral cutaneous nerve was blocked in only 75% of
subjects. Thus, threading the catheter over a shorter
distance appears to provide a consistent sensory block
of both femoral and obturator nerves which is manda-
tory for effective perioperative analgesia during TKR.
Additionally, this shorter distance could decrease the
risk of epidural distribution of local anesthetic which
has been described with a catheter inserted 24 cm.23
Further studies are needed to determine the most
appropriate length of the indwelling segment of the
catheter. The use of the stimulating catheter would be
helpful to elucidate this question.
In summary, in the present study, duration of anal-
gesia, our main endpoint, was similar when 15, 20, 25
or 30 mL ropivacaine 0.5% are used for a continuous
femoral block. However, ancillary endpoints such as
sensory extent of the block after 30 min, postoperative
local anesthetic requirements and evolution of VAS
values suggest that 20 mL (100 mg) ropivacaine 0.5%
injected via the indwelling femoral catheter threaded
blindly 12 cm in the lumbar plexus may be the most
appropriate dose for perioperative peripheral analgesia
during TKR. Larger volumes add no benefit and a
smaller volume appears to be less effective.
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